The challenges with developing therapeutic monoclonal antibodies for pandemic application

Andreas H. Laustsen; Markus-Frederik Bohn; Anne Ljungars

doi:10.1080/17460441.2021.1976141

The challenges with developing therapeutic monoclonal antibodies for pandemic application

Andreas H. Laustsen^*
, Markus-Frederik Bohn
, Anne Ljungars

^*Corresponding author for this work

Department of Biotechnology and Biomedicine

Research output: Contribution to journal › Journal article › Research › peer-review

Original language	English
Journal	Expert Opinion on Drug Discovery
Volume	17
Issue number	1
Pages (from-to)	5-8
Number of pages	4
ISSN	1746-0441
DOIs	https://doi.org/10.1080/17460441.2021.1976141
Publication status	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Epidemics
Infectious diseases
Monoclonal antibodies
Therapeutic antibodies
Pandemics

Access to Document

10.1080/17460441.2021.1976141

OpenUrl availability

Check availability in DTU Findit

Cite this

@article{2421d900260440b8aeedddb370da7346,

title = "The challenges with developing therapeutic monoclonal antibodies for pandemic application",

keywords = "Epidemics, Infectious diseases, Monoclonal antibodies, Therapeutic antibodies, Pandemics",

author = "Laustsen, \{Andreas H.\} and Markus-Frederik Bohn and Anne Ljungars",

year = "2022",

doi = "10.1080/17460441.2021.1976141",

language = "English",

volume = "17",

pages = "5--8",

journal = "Expert Opinion on Drug Discovery",

issn = "1746-0441",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - The challenges with developing therapeutic monoclonal antibodies for pandemic application

AU - Laustsen, Andreas H.

AU - Bohn, Markus-Frederik

AU - Ljungars, Anne

PY - 2022

Y1 - 2022

KW - Epidemics

KW - Infectious diseases

KW - Monoclonal antibodies

KW - Therapeutic antibodies

KW - Pandemics

U2 - 10.1080/17460441.2021.1976141

DO - 10.1080/17460441.2021.1976141

M3 - Journal article

C2 - 34503379

SN - 1746-0441

VL - 17

SP - 5

EP - 8

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

IS - 1

ER -